1. Pfizer signs deal with Gilead to manufacture COVID19 antiviral remdesivir — Biogen gets speedy FDA review for Alzheimer's med — Roche Tecentriq--chemo combo fails in triple negative breast cancer — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Are we the next Dendreon?

Discussion in 'ARIAD' started by Anonymous, Aug 14, 2014 at 9:04 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Uncertain future and idiots in charge - seems like the same formula?
     

  2. Anonymous

    Anonymous Guest

    If you are from MGI, yes.
     
  3. Anonymous

    Anonymous Guest

    yes
     
  4. Anonymous

    Anonymous Guest

    No, you are the next Eisai!
     
  5. Anonymous

    Anonymous Guest

    Oh....is ariad launching two new compounds this year, with an additional indication to immediately follow like ayzi!?
     
  6. Anonymous

    Anonymous Guest

    My bet is ARIAD gone by the end of summer. Gone meaning bought for $20/share. The rumors continue to swirl.
     
  7. anonymous

    anonymous Guest

    You still around?
     
  8. anonymous

    anonymous Guest

    $20 a share is too good for them it seems. They're still around, but as of the date of this post, the stock price is under $10.

    Further, they seem desperate to hire PhD-level people within a Clin Dev and Safety, but it doesn't seem like they're having much luck, and give these postings, who can blame candidates from staying away?